Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune Cell Associations with Cancer Risk.
Palomero L, Galván-Femenía I, de Cid R, Espín R, Barnes DR, Cimba, Blommaert E, Gil-Gil M, Falo C, Stradella A, Ouchi D, Roso-Llorach A, Violan C, Peña-Chilet M, Dopazo J, Extremera AI, García-Valero M, Herranz C, Mateo F, Mereu E, Beesley J, Chenevix-Trench G, Roux C, Mak T, Brunet J, Hakem R, Gorrini C, Antoniou AC, Lázaro C, Pujana MA. Palomero L, et al. iScience. 2020 Jul 24;23(7):101296. doi: 10.1016/j.isci.2020.101296. Epub 2020 Jun 20. iScience. 2020. PMID: 32622267 Free PMC article.
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M, Prat A. Pernas S, et al. Front Oncol. 2019 Aug 6;9:707. doi: 10.3389/fonc.2019.00707. eCollection 2019. Front Oncol. 2019. PMID: 31448227 Free PMC article.
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M, Prat A. Pernas S, et al. Front Oncol. 2019 Sep 25;9:967. doi: 10.3389/fonc.2019.00967. eCollection 2019. Front Oncol. 2019. PMID: 31598491 Free PMC article.
Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Garcia-Tejedor A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, Perez-Montero H, Fernandez-Montolí E, Stradella A, Recalde S, Soler T, Petit A, Bajen MT, Benitez A, Guma A, Campos M, Pla MJ, Martinez E, Laplana M, Pernas S, Perez-Sildekova D, Catala I, Ponce J, Falo C. Garcia-Tejedor A, et al. Breast Cancer Res Treat. 2021 Feb;185(3):657-666. doi: 10.1007/s10549-020-05970-2. Epub 2020 Oct 17. Breast Cancer Res Treat. 2021. PMID: 33068198
The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
Ortega Expósito C, Falo C, Pernas S, Pérez Carton S, Gil Gil M, Ortega R, Pérez Montero H, Stradella A, Martinez E, Laplana M, Salinas S, Luzardo A, Soler T, Fernández Montoli ME, Azcarate J, Guma A, Petit A, Benitez A, Bajen M, Reyes Junca JG, Campos M, Ruiz R, Ponce J, Pla MJ, García Tejedor A. Ortega Expósito C, et al. Breast Cancer Res Treat. 2021 Aug;189(1):111-120. doi: 10.1007/s10549-021-06274-9. Epub 2021 Jun 4. Breast Cancer Res Treat. 2021. PMID: 34089119
Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.
Stradella A, Gargallo P, Cejuela M, Petit A, Bosch-Schips J, Carbonell P, Recalde S, Vethencourt A, Fernandez-Ortega A, Falo C, Gil-Gil M, Vázquez S, Obadia V, Villanueva-Vázquez R, Soler-Monsó T, Calabria I, Pernas S. Stradella A, et al. Mod Pathol. 2022 Aug;35(8):1066-1074. doi: 10.1038/s41379-022-01017-7. Epub 2022 Feb 17. Mod Pathol. 2022. PMID: 35177782 Free article.
Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Garcia-Tejedor A, Falo C, Fernandez-Gonzalez S, Laplana M, Gil-Gil M, Soler-Monso T, Martinez-Perez E, Calvo I, Calpelo H, Bajen MT, Benitez A, Ortega R, Petit A, Guma A, Campos M, Stradella A, Lopez-Ojeda A, Ponce J, Pla MJ, Pernas S. Garcia-Tejedor A, et al. Among authors: gil gil m. Breast Cancer Res Treat. 2023 Jun;199(3):445-456. doi: 10.1007/s10549-023-06926-y. Epub 2023 Apr 12. Breast Cancer Res Treat. 2023. PMID: 37043108
Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease.
Falo C, Azcarate J, Fernandez-Gonzalez S, Perez X, Petit A, Perez H, Vethencourt A, Vazquez S, Laplana M, Ales M, Stradella A, Fullana B, Pla MJ, Gumà A, Ortega R, Varela M, Pérez D, Ponton JL, Cobo S, Benitez A, Campos M, Fernández A, Villanueva R, Obadia V, Recalde S, Soler-Monsó T, Lopez-Ojeda A, Martinez E, Ponce J, Pernas S, Gil-Gil M, Garcia-Tejedor A. Falo C, et al. Among authors: gil gil m. Cancers (Basel). 2024 Jun 30;16(13):2421. doi: 10.3390/cancers16132421. Cancers (Basel). 2024. PMID: 39001483 Free PMC article.
90 results